IPSC
NASDAQCentury Therapeutics Inc.
Price$2.14-0.28 (-11.57%)
2026-03-042026-06-05
News · 26 weeks57-60%
2025-12-142026-06-07
Mix3190d
- Insider12(39%)
- SEC Filings10(32%)
- Other7(23%)
- Leadership1(3%)
- Analyst1(3%)
Latest news
25 items- PRA Third Cancer Drug Just Entered the Clinic at an Under-$20-Million CompanyEquity Insider News CommentaryIssued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP)SAN FRANCISCO, June 2, 2026 /CNW/ -- Most clinical-stage cancer companies with three drugs dosing patients in human trials carry valuations in the hundreds of millions, or more. GT Biopharma, Inc. (NASDAQ:GTBP) recently put its third drug into the clinic — and the entire company has at times been valued at a small fraction of that. The gap between what the company is doing in the lab and what the market is paying for it is the whole story here, and a milestone reached in mid-May has brought it into sharp focus.
- ANALYSTMizuho initiated coverage on Century Therapeutics with a new price targetMizuho initiated coverage of Century Therapeutics with a rating of Outperform and set a new price target of $8.00
- SECSEC Form 424B7 filed by Century Therapeutics Inc.424B7 - Century Therapeutics, Inc. (0001850119) (Filer)
- INSIDERPresident and CEO Pfeiffenberger Brent covered exercise/tax liability with 31,172 shares, decreasing direct ownership by 0.84% to 3,679,786 units (SEC Form 4) to satisfy withholding tax4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Century Therapeutics Inc.SCHEDULE 13G/A - Century Therapeutics, Inc. (0001850119) (Subject)
- SECSEC Form SCHEDULE 13G filed by Century Therapeutics Inc.SCHEDULE 13G - Century Therapeutics, Inc. (0001850119) (Subject)
- PRCorbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of DirectorsNORWOOD, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced the appointment of Brent Pfeiffenberger, PharmD, MBA, to the Company's Board of Directors. "Brent is an accomplished pharma industry leader with deep expertise across research, development, and commercialization of life-saving drugs," said Rachelle Jacques, Chair of the Corbus Board of Directors. "His proven record of delivering value-generating commercial successes and steering notable corporate evolutions adds distinctive perspective to the Corbus Board. We look forward to Bre
- SECCentury Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Century Therapeutics, Inc. (0001850119) (Filer)
- SECSEC Form 10-Q filed by Century Therapeutics Inc.10-Q - Century Therapeutics, Inc. (0001850119) (Filer)
- PRCentury Therapeutics Reports First Quarter Financial Results and Business UpdatesCNTY-813, Century's type 1 diabetes iPSC-derived islet therapy with functional-cure potential, remains on track for IND in 4Q 2026; initial clinical data expected in 2H 2027Upcoming oral presentation at the American Diabetes Association (ADA) annual Scientific Sessions highlighting CNTY‑813 preclinical data on June 8, 2026On track to advance CNTY‑308, Century's CD19‑targeted CAR‑iT cell therapy, into the clinic this yearCash runway into 1Q 2029 with cash, cash equivalents, and marketable securities of $217.0 million as of March 31, 2026 PHILADELPHIA, May 13, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), a biotechnology company developing induced pluripoten
- INSIDERSVP Finance & Operations Carr Douglas sold $618 worth of shares (264 units at $2.34), decreasing direct ownership by 0.05% to 506,997 units (SEC Form 4) (for withholding tax)4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- PRCentury Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific SessionsPHILADELPHIA, April 30, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer, today announced the company will deliver an oral presentation at the American Diabetes Association (ADA) 86th Scientific Sessions, taking place June 5–8, 2026 in New Orleans, Louisiana. The presentation will highlight CNTY-813, Century's iPSC-derived islet cell replacement therapy program engineered with Allo-Evasion™ 5.0 for patients with type 1 diabetes. "We are building CNTY-813 with scalability and patient access in mind from d
- SECSEC Form DEFA14A filed by Century Therapeutics Inc.DEFA14A - Century Therapeutics, Inc. (0001850119) (Filer)
- SECSEC Form DEF 14A filed by Century Therapeutics Inc.DEF 14A - Century Therapeutics, Inc. (0001850119) (Filer)
- SECSEC Form PRE 14A filed by Century Therapeutics Inc.PRE 14A - Century Therapeutics, Inc. (0001850119) (Filer)
- INSIDERSEC Form 4 filed by Murphy Martin Patrick4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- INSIDERSEC Form 3 filed by new insider Murphy Martin Patrick3 - Century Therapeutics, Inc. (0001850119) (Issuer)
- INSIDERSEC Form 4 filed by Cowan Chad4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- SECCentury Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Century Therapeutics, Inc. (0001850119) (Filer)
- SECSEC Form 424B5 filed by Century Therapeutics Inc.424B5 - Century Therapeutics, Inc. (0001850119) (Filer)
- INSIDERSVP Finance & Operations Carr Douglas sold $17,953 worth of shares (7,043 units at $2.55), decreasing direct ownership by 1% to 507,261 units (SEC Form 4)4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- INSIDEROfficer Russotti Gregory sold $25,684 worth of shares (10,076 units at $2.55), decreasing direct ownership by 2% to 515,427 units (SEC Form 4)4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- INSIDERPresident and CEO Pfeiffenberger Brent covered exercise/tax liability with 55,397 shares, decreasing direct ownership by 1% to 3,710,958 units (SEC Form 4)4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- INSIDERChief Scientific Officer Cowan Chad covered exercise/tax liability with 1,431 shares, decreasing direct ownership by 0.12% to 1,177,045 units (SEC Form 4)4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- SECSEC Form S-8 filed by Century Therapeutics Inc.S-8 - Century Therapeutics, Inc. (0001850119) (Filer)
IPSC FAQ
7 questionsWhat does Century Therapeutics Inc. do?
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT or CAR-iNK candidate targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and...Where does IPSC stock trade?
Century Therapeutics Inc. (IPSC) is listed on NASDAQ.What sector and industry is IPSC in?
Century Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Century Therapeutics Inc. go public?
Century Therapeutics Inc. (IPSC) completed its IPO in 2021.What are analysts saying about IPSC?
Century Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Mizuho: Outperform with a $800.00 price target on 2026-05-27.What companies are similar to IPSC?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare IPSC side-by-side with any of them on Quantisnow.How can I track IPSC on Quantisnow?
Quantisnow aggregates Century Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IPSC to receive live email and push alerts on every new disclosure.